ABPI response to Johnson & Johnson COVID vaccine approval

28 May 2021 Posted in News by Press Office

The UK medicines regulator, the MHRA, has today approved Johnson & Johnson's single-dose vaccine for COVID-19. It becomes the fourth vaccine approved for use in the UK. 

The world needs multiple vaccines to bring an end to the pandemic, so it is great news to see the work of more companies coming to fruition. ABPI Chief Executive Richard Torbett

ABPI Chief Executive Richard Torbett welcomed the announcement.

“It’s great news that today we have the Johnson &Johnson one-shot vaccine approved by the MHRA to help fight COVID-19.

“The world needs multiple vaccines to bring an end to the pandemic, so it is great news to see the work of more companies coming to fruition.”

TAGS
  • COVID 19

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​